Impact of a Sensory Rehabilitation Program on Olfactory-gustatory Alterations in Patients Treated With Chemotherapy for Haematological Cancer

Impact of a Sensory Rehabilitation Program on Olfactory-gustatory Alterations in Patients Treated With Chemotherapy for Haematological Cancer

Proposition of a sensory rehabilitation program that could reduce the olfactory-gustatory alterations in patients who have been treated with chemotherapy for Haematological Cancer, and also improve their life quality, psychological well-being, and nutrition.

Disturbances in taste and smell affect a considerable proportion of patients treated with chemotherapy. In hematology, dysgeusia depends on the type pathology and the treatments themselves. It impacts the quality of life, leads to significant emotional and social consequences, affects the intake, weight and nutritional status of patients.

Olfactory-taste disorders can be assessed using subjective and objective tests. There are no international clinical recommendations for the management of taste and olfactory disturbances associated with chemotherapy in hematological cancers. Also, this study proposes to evaluate a taste and olfaction rehabilitation program based on national standards and recent research. It will help fill gaps in the assessment and management of patients treated for Haematological cancer.

Hypothesis is that this sensory rehabilitation program should make it possible to reduce the olfactory-gustatory changes in patients who have been treated with Chemotherapy for Haematological cancer and significantly improve their quality of life, their psychological well-being and their nutrition.

Inclusion Criteria:

• Age between 18 and ≤ 75 years old
• Patient with olfactory or gustatory disorders
• Patient who has completed chemotherapy for haematological cancer

Exclusion Criteria:

• Eating disorder known prior to anti-cancer treatment, bulimic, anorexic or binge eating disorder (DSM-V criteria)
• Refusal to sign the free and informed consent
• Hypersensitivity to one of the components of liposomal sprays (Liposaliva® or liponasal®)
• COVID + patient in the previous 3 months
• Performance status ECOG 3 or 4
• Patient included in another clinical trial modifying taste / olfaction
• Artificial nutrition post-chemotherapy
• Known food allergies
• Having a reading level in French that may interfere with a good understanding of the protocol and the questionnaires
• Presenting visual or hearing deficits uncorrected to normal and which may affect the proper completion of the questionnaires
• Patient under curatorship or tutorship.
• Patient deprived of liberty
• Pregnant or breastfeeding patient
• Not be affiliated with a French social security scheme or beneficiary of such a scheme